Keryx Biopharma (KERX) Posts Narrower than Expected Q2 Loss of 2c/Share

Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) reported Q2 EPS of ($0.02), $0.07 better than the analyst estimate of ($0.09).

For earnings history and earnings-related data on Keryx Biopharmaceuticals, Inc. (KERX) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Etsy upgraded to buy at BofA on durable growth, buyback potential
• ACRES Commercial Realty says labor dispute is hindering hotel sale
• Ross Stores raises 2026 outlook after strong second-quarter results